FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT					ATTORNEY DOCKET NO. VB60298		SERIAL NO. 10/560,513	
					APPLICANT: GARCON, Nathalie Marie-Josephe, et al.			
					FILING DATE: December 13, 2005		GROUP 1645	
		T	U.S. PA	TENT D	OCUMENTS			
Examiner Initials		Patent Number	Issue Date		Name	Class	Subclass	Filing Date If Appropriate
								<u> </u>
								<u> </u>
	1		Con	tinue on p	page	L		
	T		FOREIGN	PATENT	T DOCUMENTS			
		Document Number	Publication		Country	Class	Substage	Translation
		Tumber	Date		Country	Class	Subclass	Yes No
				7.1.				
				tinue on p				
		OTHER DOCUM	MENTS (Including I., PCPP as a paren	Author,	Title, Journal-Dat	te, Page Numbe	r, Etc.)	
	1.	(1998).	., FOPP as a paren	tai aujuv	ant for diverse an	ugens, Dev Bio	i Stand, vol. 92	2, 79-87
		C. Von Hunolste	in, et al., <i>The adju</i> v	ant effec	ct of synthetic olig	odeoxynucleot	ide containing	CpG motif
	converts the anti-Haemophilus influenzae type b glycoconjugates into efficient anti-polys 2. and anti-carrier polyvalent vaccines, Vaccine, vol. 19, 3058-3066 (2001).							accharide
	D. L. Watson, et al., Influence of adjuvants on the immune response of sheep to a novel 3. Staphylococcus aureus vaccine, Veterinary Microbiology, vol. 34, 139-153 (1993). GLAXOSMITHKLINE NZ LTD, Datasheet – Hiberix, New Zealand Medicines And Medical Device							
	4.	Authority (2002).						•
	5.	Aldrich Handboo 1529-1530.	ok of Fine Chemica	is and La	aboratory Equipme	ent, 2003-2004,	United Kingdo	om, pp.
	<u> </u>		bable Polymers MS	SDS for 5	0:50 poly(DL-lacti	de-co-alvcolide). April 8, 2008	from
	•	Birmingham Pol	ymers, www.birmin	nghampo	lymers.com, wwv	v.absorbables.c	om/document	ts/DL-
	6.	PLGMSDS.pdf						
			0					
			Cont	tinue on p	page			
EXAMINER		/Jennif	er Graser/			DATE CO	NSIDERED	10/30/2008
EXAMINER:	Initia	l if citation conside e and not considere	red, whether or not o	citation is	s in conformance with next communi	ith MPEP § 609	Draw line thro	ough citation